Beximco Pharmaceuticals Limited
BXP.L · LSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.41 | 0.18 | 0.54 | -0.91 |
| FCF Yield | -1.07% | 8.07% | 4.42% | 7.42% |
| EV / EBITDA | 11.77 | 6.24 | 13.23 | 12.31 |
| Quality | ||||
| ROIC | 2.92% | 3.10% | 2.68% | 2.46% |
| Gross Margin | 45.29% | 46.17% | 44.36% | 43.72% |
| Cash Conversion Ratio | 0.57 | 1.01 | – | 1.56 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.43% | 7.69% | 8.59% | 8.58% |
| Free Cash Flow Growth | -120.18% | 21.11% | -33.26% | 33.08% |
| Safety | ||||
| Net Debt / EBITDA | 1.74 | 0.42 | 1.79 | 2.63 |
| Interest Coverage | 12.05 | 9.21 | 7.21 | 6.84 |
| Efficiency | ||||
| Inventory Turnover | 0.45 | 0.45 | 0.48 | 0.46 |
| Cash Conversion Cycle | 191.61 | 198.18 | 184.49 | 161.51 |